WO2019148249A1 - Compositions for treating infective arterial diseases and related conditions - Google Patents

Compositions for treating infective arterial diseases and related conditions Download PDF

Info

Publication number
WO2019148249A1
WO2019148249A1 PCT/AU2019/050078 AU2019050078W WO2019148249A1 WO 2019148249 A1 WO2019148249 A1 WO 2019148249A1 AU 2019050078 W AU2019050078 W AU 2019050078W WO 2019148249 A1 WO2019148249 A1 WO 2019148249A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
dementia
optionally
arterial
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2019/050078
Other languages
French (fr)
Inventor
Thomas Julius Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Digestive Diseases Pty Ltd
Original Assignee
Centre for Digestive Diseases Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Digestive Diseases Pty Ltd filed Critical Centre for Digestive Diseases Pty Ltd
Priority to CN201980006904.6A priority Critical patent/CN111757732A/en
Priority to EP19747153.5A priority patent/EP3746073A4/en
Priority to AU2019214017A priority patent/AU2019214017A1/en
Priority to CA3086850A priority patent/CA3086850A1/en
Priority to US16/958,299 priority patent/US20210052557A1/en
Publication of WO2019148249A1 publication Critical patent/WO2019148249A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention generally relates to medicine and infectious disease.
  • one common pathogen targeted by compositions and methods as provided herein is Chlamydia and Chlamydophila species, including pneumoniae , trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae which also infects humans.
  • pathogens targeted and infections treated, ameliorated, or prevented by compositions and methods as provided herein include Mycoplasma, Listeria , Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease.
  • Vascular disease such as coronary heart disease and stroke remain the major cause of morbidity and mortality worldwide. Particularly in China the escalating numbers of patients with coronary and peripheral artery disease has been described as being of epidemic proportions.
  • CAD coronary heart disease
  • peripheral vascular disease are currently treated by identifying and targeting‘risk factors’ since these are the only parameters to treat in the absence of an underlying cause of these conditions.
  • myocardial infarction tissues/muscle which is called‘myocardial infarction’ - and may be accompanied by severe pain, and arrythmias. When this happens in the brain it is called‘ischemic stroke’.
  • ischemic stroke A similar process may also take place in peripheral vessels such as leg and foot vessels, causing them to be cold, painful, lose sensation or ultimately necrosis of toes.
  • Chlamydophila pneumoniae a name interchangeable with Chlamydia pneumonia, has only been recently described, and is known as a microorganism which can infect numerous tissues. It is responsible for up to one third of community acquired pneumonia, bronchitis, chronic obstructive airways disease and asthma, and has now been recognised to be present in atherosclerotic plaque.
  • Cpn has been incriminated in causality of the inflammation in the lungs and arteries and may well be the cause of the known arterial inflammation that predates plaque development and so causes vascular disease such as coronary heart disease.
  • Cpn Chlamydophila pneumoniae is capable of using cholesterol, and in its metabolic cycles Cpn is capable of producing cells containing lipids and so it causes foam cells to appear at the site of the formation of atherosclerotic plaque. This explains better the relationship of cholesterol and fats in the blood vessel and the action of Cpn, and explains why arterial wall lipid deposition is related to food-derived cholesterol and triglycerides.
  • Cpn is an obligate intracellular pathogen that grows within macrophages and in vessel wall cells including muscle cells.
  • Chlamydia infections such as Chlamydia trachomatis can cause acute infections such as conjunctivitis, sexually transmitted diseases, as well as chronic infection that can lead to trachoma, tubal infection and infertility, pelvic inflammatory disease, and reactive arthritis.
  • acute infections are localised in the airways with pneumonia and bronchitis being the most common condition.
  • the chronic sequelae developing from acute or from asymptomatic infections cannot be at times definitively attributed to Cpn.
  • evidence is accumulating that it may lead to debilitating asthma and even fatal heart disease conditions. It may also cause reactive arthritis, possibly late onset Alzheimer's disease, multiple sclerosis and complications of these diseases.
  • Cpn like other members of the genus has the characteristic biphasic lifecycle between the infectious, metabolically inert elementary body (EB) and the non-infectious metabolically active reticulate body (RD).
  • EB's are internalised into the pathogen modified phagosomes which avoid destruction with lysosomes. This is referred to as an inclusion and this ability of Cpn to enter non-productive growth state is often termed persistence or dormancy.
  • Not all persons infected with Cpn develop vascular disease or asthma, however recovery rates of the microorganisms have ranged between 20% and 60% of sites of atherosclerotic tissue and up to 100% when serial histology sections are taken. The organism has not been recovered from normal vascular tissue. Animal models have been developed, in which infection with Cpn is followed in an accelerated fashion by development of atherosclerotic plaque.
  • Tetracyclines have been used as monotherapy but without clinical benefit and since then it has been discovered that the bacteriostatic tetracyclines may convert the metabolically- active reticulate bodies (RB) into a metabolically-inactive elementary body (EB), which is metabolically inert and less affected by antibiotics.
  • RB metabolically- active reticulate bodies
  • EB metabolically-inactive elementary body
  • Persistent chlamydial infections can be established in vitro using some cytokines, antibiotics and by deprivation of certain nutrients. This may also be occurring in vivo.
  • growth inhibitory factors When growth inhibitory factors are removed aberrant bodies which are reticulate bodies ( RBs ) in atypical form can be restored to normal.
  • RBs reticulate bodies
  • the characteristic of persistent Cpn infection is the development of large RB forms along with the absence of EB's.
  • the Cpn organisms fall into a‘persistent state’.
  • the presence of a persistent state causes consistent presentation to that individual's immune system and could lead to potentially deleterious immune affects such as chronic arthritis and inflammation in arteries.
  • compositions, formulations, or products of manufacture comprising at least three different antibiotics selected from the group consisting of:
  • a macrolide e.g., azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin
  • a quinolone e.g., fluoroquinolone
  • chloramphenicol e.g., PENTAMYCETINTM
  • CHLOROMYCETINTM a cephalosporin
  • a nitazoxanide e.g., ALINIATM, NIZONIDETM
  • a furazolidone e.g., FUROXONETM, DEPEND AL-MTM
  • a lincomycin or clindamycin e.g., CLEOCINTM, CLINACINTM
  • an aminoglycoside e.g., streptomycin
  • a carbapenem e.g., imipenem, meropenem, ertapenem, doripenem, panipenem or betamipron, biapenem, tebipenem
  • a glycopeptide e.g., vancomycin, teicoplanin, telavancin, ramoplanin, decaplanin
  • a glycocycline e.g., tigecycline
  • a streptogramin e.g., quinupristin/
  • sulfametoxydiazine sulfadoxine, sulfametopyrazine, terephtyl
  • an oxazolidinone e..g., 2- oxazolidone, linezolid, posizolid, tedizolid, radezolid, cycloserine
  • a nitroimidazole e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, omidazole, megazol, azanidazole
  • rifalazil, rifabutin e.g., MYCOBUTINTM
  • omiganan or omiganan pentahydrochloride
  • radezolid RX-1741
  • torezolid RWJ-416457
  • ceftobiprole or ZEVTERATM, MABELIOTM
  • a nitrofuran e.g., difurazone, furazolidone, nifurfoline, nifuroxazide, nifurquinazol
  • isoniazid e.g., HYDRATM, HYZYDTM, ISOVITTM
  • ceftaroline e.g., ceftaroline fosamil, or
  • tinidazole e.g., FASIGYNTM, SIMPLOTANTM, TINDAMAXTM
  • ornidazole e.g., XYNORTM
  • secnidazole e.g., FLAGENTYL, SINDOSETM, SECNITML, SOLOSECTM
  • roxithromycin doxycycline (e.g., DORYXTM, DOXYHEXALTM, DOXYLINTM), minocycline (e.g., MINOCINTM, MINOMYCINTM, AKAMINTM), clarithromycin (e.g., BIAXINTM) and/or nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, ornidazole, megazol, azanidazole) is the at least fourth antibiotic,
  • nitroimidazole is formulated for administration to be cycled 2 weeks on and 2 weeks off.
  • the at least three different antibiotics comprises:
  • (f) comprises rifabutin, azithromycin and minocycline.
  • compositions, formulation, or a product of manufacture comprising:
  • a macrolide e.g., azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin
  • a quinolone e.g., fluoroquinolone
  • chloramphenicol e.g.,
  • PENTAMYCETINTM CHLOROMYCETINTM
  • a cephalosporin e.g., a cephalosporin
  • a nitazoxanide e.g., a nitazoxanide
  • ALINIATM, NIZONIDETM a furazolidone
  • a furazolidone e.g., FUROXONETM, DEPEND AL-MTM
  • a lincomycin or clindamycin e.g., CLEOCINTM, CLINACINTM
  • an aminoglycoside e.g., streptomycin
  • carbapenem e.g., imipenem, meropenem, ertapenem, doripenem, panipenem or betamipron, biapenem, tebipenem
  • a glycopeptide e.g., vancomycin, teicoplanin, telavancin, ramoplanin, decaplanin
  • a glycocycline e.g., tigecycline
  • streptogramin e.g.,
  • quinupristin/dalfopristin quinupristin/dalfopristin, pristinamycin, virginiamycin
  • a rifamycin e.g., rifampicin (or rifampin), rifabutin, rifapentine, rifalazil, rifaximin, rifamycin SV (or AEMCOLOTM)
  • an ansamycin e.g., streptovaricin, geldanamycin, rifamycin
  • a sulphonamide e.g.,
  • sulfadimethoxine sulfamethoxypyridazine, sulfametoxydiazine, sulfadoxine, sulfametopyrazine, terephtyl
  • an oxazolidinone e..g., 2-oxazolidone, linezolid, posizolid, tedizolid, radezolid, cycloserine
  • a nitroimidazole e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, omidazole, megazol, azanidazole
  • rifalazil e.g., MYCOBUTINTM
  • rifabutin e.g., MYCOBUTINTM
  • omiganan or omiganan
  • ZEVTERATM, MABELIOTM a nitrofuran (e.g., difurazone, furazolidone, nifurfoline, nifuroxazide, nifurquinazol), isoniazid (e.g., HYDRATM, HYZYDTM, ISOVITTM), ceftaroline (e.g., ceftaroline fosamil, or TEFLAROTM, ZINFOROTM), iclaprim, garenoxacin, cethromycin (e.g., RESTANZATM) and/or telithromycin (e.g., KETEKTM) (part of the macrolide group), doxycycline, tigecycline (e.g., TYGACILTM), minocycline (e.g., MINOCINTM, AKAMINTM) and / or a tetracycline (e.g., SEIMYCINTM); or,
  • a metronidazole e.g., FLAGYLTM, METROTM
  • tinidazole e.g., FASIGYNTM, SIMPLOTANTM, TINDAMAXTM
  • ornidazole e.g., XYNORTM
  • secnidazole e.g., FLAGENTYL, SINDOSETM, SECNITML, SOLOSECTM
  • roxithromycin doxycycline
  • minocycline e.g., MINOCINTM, MINOMYCINTM, AKAMINTM
  • clarithromycin e.g., BIAXINTM
  • nitroimidazole e.g., metronidazole
  • metronidazole e.g., FLAGYLTM, METROTM
  • tinidazole e.g., FASIGYNTM, SIMPLOTANT
  • nitroimidazole is formulated for administration to be cycled 2 weeks on and 2 weeks off.
  • the at least three different antibiotics comprise
  • the at least three antibiotics comprise rifabutin, azithromycin and doxycycline.
  • the rifabutin, azithromycin and doxycycline may be combined with vitamin D.
  • the pharmaceutical compositions, formulations, or products of manufacture further comprises: (a) a vitamin E, a tocotrienol, a natural tocopherol or a tocochromanol, a vitamin D, or any combination thereof, wherein optionally the vitamin D is formulated for use in doses of up to about 5000 to 20,000 units per day, optionally to achieve blood levels of about 150 to 375 nmol/l; (b) a penicillamine, or DEPENTM or CUPRIMINETM; (c) an acetylcysteine or N-acetylcysteine (NAC), or ACETADOTETM, FLUIMUCILTM, MUCOMYSTTM; or (d) any combination of (a) to (c).
  • a vitamin E a tocotrienol, a natural tocopherol or a tocochromanol, a vitamin D, or any combination thereof, wherein optionally the vitamin D is formulated for use in doses of up to about 5000 to 20,000
  • Vitamin D needs to be used in higher than expected doses, as we have shown in patients, for example, at about 5000 to 20,000 units per day to achieve blood levels near the top of normal range of around 200 to 375 nmol/l. These levels are non-toxic, for toxicity to occur much higher levels need to be reached.
  • the pharmaceutical compositions, formulations, or products of manufacture further comprises: an agent selected from other medications used in the management of coronary and other vascular disease, other medications that enhance host defence mechanisms important in the eradication of intracellular pathogens, selective and non- selective cyclooxygenase inhibitors; other antiplatelet drugs; betablockers; antiarrhythmics; calcium channel blockers; other anticoagulant drugs; nitrate medicines and HMG-Coareductase inhibitors; immune response modifiers selected from cytokines; colony stimulating factors; tumour necrosis factors alpha and beta; interferon alpha, beta and gamma; peptides which bind to macrophage and lymphocyte surface receptors: glycoproteins which mimic cytokines; and other mediator molecules; prednisone and related steroids, azathioprine, mofetil mycofenolate and related purine antagonists, cyclophosphamide and related alkylating agents, methotrexate and related folate antagonists
  • the pharmaceutical compositions, formulations, or products of manufacture are formulated for parenteral or enteral delivery, or for oral delivery, optionally in a capsule, a tablet, a geltab or a solution or a liquid, or as an aerosol, wherein optionally the at least three different antibiotics, or at least two antibiotic, or all active agents are in one formulation, optionally a capsule, a tablet, a geltab or a solution or liquid.
  • the product of manufacture is an implant.
  • kits for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima or for the treatment, amelioration and prevention of:
  • Chlamydia a disease or condition caused by Chlamydia or a Chlamydophila species, including
  • the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease, the method comprising administration to an individual in need thereof a pharmaceutical composition, a formulation, or a product of manufacture as provided herein.
  • the methods further comprise administration of:
  • vitamin E or tocotrienol or equivalents optionally comprising vitamin E or tocochromanol either as a natural Tocopherol or Tocotrienol
  • optionally added in a cyclic fashion optionally from between daily to weekly administrations;
  • vitamin D optionally administered to upper limit of normal levels, optionally administered in dosages of at least about 5,000 to about 20,000 units per day, optionally until levels are reached which are also capable of killing an intracellular infectious agent and reducing intracellular persistence of the intracellular infectious agent, optionally Chlamydophila pneumonia within macrophages.
  • the pharmaceutical composition or formulation is administered parenterally or enterally, or orally, optionally in a capsule, a tablet, a geltab or a solution or a liquid, or as an aerosol, wherein optionally the at least three different antibiotics, or at least two antibiotic, or all active agents are in one formulation, optionally a capsule, a tablet, a geltab or a solution or liquid, and optionally each active agent is formulated in a separate product of manufacture, optionally each active agent in a separate capsule, tablet, geltab, solution or liquid.
  • a pharmaceutical composition, formulation, or a product of manufacture as provided herein for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for the treatment, amelioration and prevention of:
  • Chlamydia a disease or condition caused by Chlamydia or a Chlamydophila species, including
  • the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
  • compositions, formulations, products of manufacture as provided herein for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for use in the treatment, amelioration and prevention of:
  • Chlamydia a disease or condition caused by Chlamydia or a Chlamydophila species, including
  • the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
  • Chlamydia or a Chlamydophila species including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
  • the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
  • one common pathogen targeted by compositions and methods as provided herein is Chlamydia and
  • Chlamydophila species including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae which also infects humans.
  • pathogens targeted and infections (diseases) treated, ameliorated, or prevented by compositions and methods as provided herein include Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellae eae, including cat scratch disease.
  • disorders include asthma, chronic obstructive lung disease, dementia, urinary and gynaecologic mucosal Chlamydial infections.
  • Chlamydial infections including Chlamydophila pneumoniae (Cpn), or other infections as listed above, in a patient in need of such treatment or prevention.
  • Cpn Chlamydophila pneumoniae
  • compositions and methods as provided herein comprise or comprise administration to an individual (e.g., a patient or an animal) of an affective amount of at least three different antibiotics selected from the group consisting of: macrolides, quinolones, chloramphenicol, cephalosporins, nitazoxanide, furazolidones, lincomycins, aminoglycosides, carbapenems, glycopeptides, glycocyclines, isoniazid, streptogramins, rifamycins/ansamycins, sulphonamides, oxazolidinones, nitrofurans and nitroimidazoles.
  • antibiotics selected from the group consisting of: macrolides, quinolones, chloramphenicol, cephalosporins, nitazoxanide, furazolidones, lincomycins, aminoglycosides, carbapenems, glycopeptides, glycocyclines, isoniazid, streptogramins,
  • compositions and methods as provided herein comprise or comprise administration to an individual (e.g., a patient or an animal) of an affective amount of at least three different antibiotics selected from the group consisting of: clarithromycin, rifabutin and furazolidone.
  • the at least three antibiotics comprise rifabutin, azithromycin and doxycycline.
  • the rifabutin, azithromycin and doxycycline may be combined with vitamin D.
  • compositions and methods as provided herein comprise or comprise administration to an individual (e.g., a patient or an animal) of an affective amount of at least three different antibiotics selected from the group consisting of: rifalazil, rifabutin, omiganan, radezolid (RX-1741), torezolid, RWJ-416457, ceftobiprole, ceftaroline, iclaprim, garenoxacin, cethromycin and/or telithromycin (part of the macrolide group), tigecycline, minocycline and tetracycline.
  • antibiotics selected from the group consisting of: rifalazil, rifabutin, omiganan, radezolid (RX-1741), torezolid, RWJ-416457, ceftobiprole, ceftaroline, iclaprim, garenoxacin, cethromycin and/or telithromycin (part of the macrolide group),
  • Tigecycline is a novel glycylcycline, but it remains a tetracycline derivative which has good activity against Chlamydophila pneumoniae (Cpn).
  • Cpn Chlamydophila pneumoniae
  • ketolides which includes telithromycin tend to have similar high activity as
  • clarithromycin possesses, but some isolates are more sensitive than others.
  • the most active of the macrolides used in compositions and methods as provided herein is cethromycin.
  • other anti-Cpn and other infective agent medications used in compositions and methods as provided herein include vancomycin, gentamicin, rifaximin, ampicillin, streptomycin, trimethoprim/sulfamethoxazole.
  • novel inhibitors of peptide deformylase that can be used include NVP-PDF386/ABT/773 and
  • a three-drug regimen as provided herein comprises rifampicin, azithromycin and moxifloxacin, optionally in a ramping-up dose, a feature observed by the inventor to permit treatment with the combination without adverse effects.
  • a three-drug regimen as provided herein comprises rifabutin and clarithromycin.
  • a supplemental vitamin E or tocotrienol will be added in a cyclic fashion from between second daily to weekly; and these can comprise vitamin E or tocochromanol either as being a natural tocopherol or tocotrienol.
  • the addition of the vitamin E derivatives can markedly reduce the aberrant body development accelerating the destruction of Chlamydia in human lymphocytes.
  • compositions and methods also comprise the addition of vitamin D to upper limit of normal levels by ingesting at least 5,000 - 20,000 units per day, until levels are reached, which are also capable of killing the Cpn and reducing intracellular persistence of the intracellular agent.
  • the cycling of nitroimidazoles such as metronidazole, tinidazole, omidazole and secnidazole, also prevents the formation of the resistant intracellular reticulate bodies (RBs) and can be inserted to the cycling protocol of three antibiotics as the fourth antibiotic, or metronidazole, tinidazole, omidazole, secnidazole, roxithromycin, doxycycline, minocycline, clarithromycin or nitroimidazole is the fourth antibiotic can be the fourth antibiotic, in a pharmaceutical composition, formulation, or a product of manufacture as provided herein.
  • a three drug regime as provided herein comprises rifampicin, azithromycin and moxifloxacin, optionally avoiding tetracyclines as they can inhibit the production of elementary bodies.
  • compositions and methods as provided herein are used for Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease; and the compositions and methods can comprise use of: nitroimidazole, roxithromycin, doxycycline, minocycline, clarithromycin, or minocycline and clarithromycin, optionally combined with a vitamin E and/or vitamin D, optionally in a cycling fashion, or optionally including a nitroimidazole one out of two weeks, or two weeks on and two weeks off, to permit the formation of the susceptible Chlamydophila pneumoniae (Cpn) bodies.
  • the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis
  • the sestamibi scan was also improved at 3 months of combination rifabutin, azithromycin and doxycycline plus vitamin D.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

In alternative embodiments, provided are pharmaceutical compositions and methods for treatment, amelioration and prevention of infection-associated blood vessel diseases, and also for the treatment, amelioration and prevention of non-vessel diseases affected by infective agents which can be treated by these compositions. In alternative embodiments, one common pathogen targeted by compositions and methods as provided herein is Chlamydia and Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae which also infects humans. In alternative embodiments, pathogens targeted and infections (diseases) treated, ameliorated, or prevented by compositions and methods as provided herein include Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease. The compositions comprise at least three different antibiotic agents selected with compositions comprising a rifamycin (such as rifabutin), a macrolide (such as clarithromycin or azithromycin), and a tetracycline (such as doxycycline) or a nitrofuran (such as furazolidone) being preferred.

Description

COMPOSITIONS FOR TREATING INFECTIVE ARTERIAL DISEASES AND RELATED CONDITIONS
Field
[0001] This invention generally relates to medicine and infectious disease. In alternative embodiments, provided are pharmaceutical compositions and methods for treatment, amelioration and prevention of infection-associated blood vessel diseases, and also for the treatment, amelioration and prevention of non-vessel diseases affected by infective agents which can be treated by these compositions. In alternative embodiments, one common pathogen targeted by compositions and methods as provided herein is Chlamydia and Chlamydophila species, including pneumoniae , trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae which also infects humans. In alternative embodiments, pathogens targeted and infections (diseases) treated, ameliorated, or prevented by compositions and methods as provided herein include Mycoplasma, Listeria , Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease.
Background
[0002] Atypical infections as those mentioned above, infect various regions of the body and are often carried in circulating white cells such as monocytes/macrophages. They generally infect intracellular locations, for example, intima layer cells of arteries, causing chronic inflammation in arteries followed by edema, necrosis, foam cell formation which results in plaque formation. Vascular disease such as coronary heart disease and stroke remain the major cause of morbidity and mortality worldwide. Particularly in China the escalating numbers of patients with coronary and peripheral artery disease has been described as being of epidemic proportions.
[0003] Both coronary heart disease (CAD) and peripheral vascular disease are currently treated by identifying and targeting‘risk factors’ since these are the only parameters to treat in the absence of an underlying cause of these conditions.
[0004] The development of atheroma in the vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to the intima begins with visible foam cells, followed by edema or swelling, then destruction of muscle cells and necrosis with fully formed plaque projecting into the lumen of the pulsating epicardial arteries. Complications of plaque formation can follow such as partial plaque rupture and local activation of the clotting cascade which may occlude the blood vessel partially or completely. This may lead to death of distant
tissues/muscle which is called‘myocardial infarction’ - and may be accompanied by severe pain, and arrythmias. When this happens in the brain it is called‘ischemic stroke’. A similar process may also take place in peripheral vessels such as leg and foot vessels, causing them to be cold, painful, lose sensation or ultimately necrosis of toes.
[0005] Conventional therapy for vascular disease aims to open the vessel lumen and to prevent or reverse clot formation with reduction of plaque formation. Hence, the treatments and preventative therapies target risk factors such as hypertension, smoking and dyslipidaemia.
[0006] Treatment of Cpn targets an infective bacterium which can be visualised in and cultured from arterial tissue. Chlamydophila pneumoniae a name interchangeable with Chlamydia pneumonia, has only been recently described, and is known as a microorganism which can infect numerous tissues. It is responsible for up to one third of community acquired pneumonia, bronchitis, chronic obstructive airways disease and asthma, and has now been recognised to be present in atherosclerotic plaque. Hence, Cpn has been incriminated in causality of the inflammation in the lungs and arteries and may well be the cause of the known arterial inflammation that predates plaque development and so causes vascular disease such as coronary heart disease. It has also been shown that Cpn Chlamydophila pneumoniae is capable of using cholesterol, and in its metabolic cycles Cpn is capable of producing cells containing lipids and so it causes foam cells to appear at the site of the formation of atherosclerotic plaque. This explains better the relationship of cholesterol and fats in the blood vessel and the action of Cpn, and explains why arterial wall lipid deposition is related to food-derived cholesterol and triglycerides. Cpn is an obligate intracellular pathogen that grows within macrophages and in vessel wall cells including muscle cells. Infection with Cpn is characterised by intracellular persistence following the infections and it has been estimated that about 50% of the population are sero-positive for Cpn in adult life and most persons acquire the infection via the respiratory route generally in teenage years. Related Chlamydia infections such as Chlamydia trachomatis can cause acute infections such as conjunctivitis, sexually transmitted diseases, as well as chronic infection that can lead to trachoma, tubal infection and infertility, pelvic inflammatory disease, and reactive arthritis. For Cpn, acute infections are localised in the airways with pneumonia and bronchitis being the most common condition. The chronic sequelae developing from acute or from asymptomatic infections cannot be at times definitively attributed to Cpn. Although, evidence is accumulating that it may lead to debilitating asthma and even fatal heart disease conditions. It may also cause reactive arthritis, possibly late onset Alzheimer's disease, multiple sclerosis and complications of these diseases.
[0007] Cpn like other members of the genus has the characteristic biphasic lifecycle between the infectious, metabolically inert elementary body (EB) and the non-infectious metabolically active reticulate body (RD). EB's are internalised into the pathogen modified phagosomes which avoid destruction with lysosomes. This is referred to as an inclusion and this ability of Cpn to enter non-productive growth state is often termed persistence or dormancy. Not all persons infected with Cpn develop vascular disease or asthma, however recovery rates of the microorganisms have ranged between 20% and 60% of sites of atherosclerotic tissue and up to 100% when serial histology sections are taken. The organism has not been recovered from normal vascular tissue. Animal models have been developed, in which infection with Cpn is followed in an accelerated fashion by development of atherosclerotic plaque.
[0008] A number of therapies have been trialed, but generally speaking, only monotherapy has been used i.e. a single antibiotic was given to patients. Azithromycin has been used and showed some benefit, but this was not sustained. Benefit was also seen with use of roxithromycin.
Tetracyclines have been used as monotherapy but without clinical benefit and since then it has been discovered that the bacteriostatic tetracyclines may convert the metabolically- active reticulate bodies (RB) into a metabolically-inactive elementary body (EB), which is metabolically inert and less affected by antibiotics.
[0009] The use of single antibiotics in treatment of Cpn which at best is difficult to eradicate, due to is dormant forms, has the potential of causing serious adverse consequence in large populations of the world and that many will develop resistant infections for which there is really unlikely to be any effective therapies. In many cases suppression rather than eradication occurs and following the withdrawal of the antibiotics the suppressed pathogen can become reactivated and develops illness with a resistant strain.
[00010] Persistent chlamydial infections can be established in vitro using some cytokines, antibiotics and by deprivation of certain nutrients. This may also be occurring in vivo. When growth inhibitory factors are removed aberrant bodies which are reticulate bodies ( RBs ) in atypical form can be restored to normal. The characteristic of persistent Cpn infection is the development of large RB forms along with the absence of EB's. Hence, in a cell environment in which a condition of nutritional stress is created the Cpn organisms fall into a‘persistent state’. The presence of a persistent state causes consistent presentation to that individual's immune system and could lead to potentially deleterious immune affects such as chronic arthritis and inflammation in arteries. Repeated infection can also cause a similar affect as persistent infection. Removal of various antibiotics especially Penicillins, Ciprofloxacin or Ofloxacin can induce the persistence infection to be significantly decreased and allow the persistent Chlamydia to turn into infectious EB's which are more easily treatable and opens the door to better eradication. Cyclic starting and stopping some such antibiotics in a timely fashion improves recruitment into treatable state.
[00011] There is little teaching of the use of combined antibiotics. Yet with use of in vitro sensitivity testing there is no relationship to in vivo clinical result and such an approach should no longer be used. Sensitivities should still be tested but in chronic longstanding infection a minimum of three antimicrobial agents should be combined to try and prevent widespread resistance developing. Hence, there is a need for better methods of treating conditions associated with Cpn and other infections mentioned above. There is also a need to treat the initial infection effectively with a combination of antibiotics to prevent it going into a chronic phase with consequences of ongoing disease and heightened bacteria resistance.
Summary of Invention
[00012] In alternative embodiments, provided are pharmaceutical compositions, formulations, or products of manufacture, comprising at least three different antibiotics selected from the group consisting of:
(a)
(i) a macrolide (e.g., azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin), a quinolone (e.g., fluoroquinolone), chloramphenicol (e.g., PENTAMYCETIN™,
CHLOROMYCETIN™), a cephalosporin, a nitazoxanide (e.g., ALINIA™, NIZONIDE™), a furazolidone (e.g., FUROXONE™, DEPEND AL-M™), a lincomycin or clindamycin (e.g., CLEOCIN™, CLINACIN™), an aminoglycoside (e.g., streptomycin), a carbapenem (e.g., imipenem, meropenem, ertapenem, doripenem, panipenem or betamipron, biapenem, tebipenem), a glycopeptide (e.g., vancomycin, teicoplanin, telavancin, ramoplanin, decaplanin), a glycocycline (e.g., tigecycline), a streptogramin (e.g., quinupristin/dalfopristin, pristinamycin, virginiamycin), a rifamycin (e.g., rifampicin (or rifampin), rifabutin, rifapentine, rifalazil, rifaximin, rifamycin SV (or AEMCOLO™)) an ansamycin (e.g., streptovaricin, geldanamycin, rifamycin), a sulphonamide (e.g., sulfadimethoxine, sulfamethoxypyridazine,
sulfametoxydiazine, sulfadoxine, sulfametopyrazine, terephtyl), an oxazolidinone (e..g., 2- oxazolidone, linezolid, posizolid, tedizolid, radezolid, cycloserine) and/or a nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, omidazole, megazol, azanidazole); or
(ii) rifalazil, rifabutin (e.g., MYCOBUTIN™), omiganan (or omiganan pentahydrochloride), radezolid (RX-1741), torezolid, RWJ-416457, ceftobiprole (or ZEVTERA™, MABELIO™), a nitrofuran (e.g., difurazone, furazolidone, nifurfoline, nifuroxazide, nifurquinazol), isoniazid (e.g., HYDRA™, HYZYD™, ISOVIT™), ceftaroline (e.g., ceftaroline fosamil, or
TEFLARO™, ZINFORO™), iclaprim, garenoxacin, cethromycin (e.g., RESTANZA™) and/or telithromycin (e.g., KETEK™) (part of the macrolide group), doxycycline, tigecycline (e.g., TYGACIL™), minocycline (e.g., MINOCIN™, AKAMIN™) and / or a tetracycline (e.g., SUMYCIN™); or,
(iii) a combination of (i) and (ii);
(b) the pharmaceutical composition, formulation, or a product of manufacture of (a), further comprising at least four antibiotics, and optionally a metronidazole (e.g., FLAGYL™,
METRO™), tinidazole (e.g., FASIGYN™, SIMPLOTAN™, TINDAMAX™), ornidazole (e.g., XYNOR™), secnidazole (e.g., FLAGENTYL, SINDOSE™, SECNI™L, SOLOSEC™), roxithromycin, doxycycline (e.g., DORYX™, DOXYHEXAL™, DOXYLIN™), minocycline (e.g., MINOCIN™, MINOMYCIN™, AKAMIN™), clarithromycin (e.g., BIAXIN™) and/or nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, ornidazole, megazol, azanidazole) is the at least fourth antibiotic,
and optionally the nitroimidazole is formulated for administration to be cycled 2 weeks on and 2 weeks off.
[00013] In alternative embodiments, the at least three different antibiotics comprises:
(a) rifampicin, azithromycin and moxifloxacin, optionally in a ramping-up dose (or formulated for a ramping up dosage regimen);
(b) at least comprises rifabutin, and clarithromycin or azithromycin; (c) at least comprises rifabutin and minocycline;
(d) at least comprises rifabutin and azithromycin;
(e) at least comprises rifabutin and clarithromycin; or
(f) comprises rifabutin, azithromycin and minocycline.
[00014] In alternative embodiments, provided is a pharmaceutical composition, formulation, or a product of manufacture, comprising:
(a) at least three different antibiotics selected from the group consisting of:
(i) a macrolide (e.g., azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin), a quinolone (e.g., fluoroquinolone), chloramphenicol (e.g.,
PENTAMYCETIN™, CHLOROMYCETIN™), a cephalosporin, a nitazoxanide (e.g.,
ALINIA™, NIZONIDE™), a furazolidone (e.g., FUROXONE™, DEPEND AL-M™), a lincomycin or clindamycin (e.g., CLEOCIN™, CLINACIN™), an aminoglycoside (e.g., streptomycin), a carbapenem (e.g., imipenem, meropenem, ertapenem, doripenem, panipenem or betamipron, biapenem, tebipenem), a glycopeptide (e.g., vancomycin, teicoplanin, telavancin, ramoplanin, decaplanin), a glycocycline (e.g., tigecycline), a streptogramin (e.g.,
quinupristin/dalfopristin, pristinamycin, virginiamycin), a rifamycin (e.g., rifampicin (or rifampin), rifabutin, rifapentine, rifalazil, rifaximin, rifamycin SV (or AEMCOLO™)) an ansamycin (e.g., streptovaricin, geldanamycin, rifamycin), a sulphonamide (e.g.,
sulfadimethoxine, sulfamethoxypyridazine, sulfametoxydiazine, sulfadoxine, sulfametopyrazine, terephtyl), an oxazolidinone (e..g., 2-oxazolidone, linezolid, posizolid, tedizolid, radezolid, cycloserine) and/or a nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, omidazole, megazol, azanidazole); or
(ii) rifalazil, rifabutin (e.g., MYCOBUTIN™), omiganan (or omiganan
pentahydrochloride), radezolid (RX-1741), torezolid, RWJ-416457, ceftobiprole (or
ZEVTERA™, MABELIO™), a nitrofuran (e.g., difurazone, furazolidone, nifurfoline, nifuroxazide, nifurquinazol), isoniazid (e.g., HYDRA™, HYZYD™, ISOVIT™), ceftaroline (e.g., ceftaroline fosamil, or TEFLARO™, ZINFORO™), iclaprim, garenoxacin, cethromycin (e.g., RESTANZA™) and/or telithromycin (e.g., KETEK™) (part of the macrolide group), doxycycline, tigecycline (e.g., TYGACIL™), minocycline (e.g., MINOCIN™, AKAMIN™) and / or a tetracycline (e.g., SEIMYCIN™); or,
(iii) a combination of (i) and (ii); or (b) the pharmaceutical composition, formulation, or a product of manufacture of (a), further comprising at least a fourth antibiotic, and optionally a metronidazole (e.g., FLAGYL™, METRO™), tinidazole (e.g., FASIGYN™, SIMPLOTAN™, TINDAMAX™), ornidazole (e.g., XYNOR™), secnidazole (e.g., FLAGENTYL, SINDOSE™, SECNI™L, SOLOSEC™), roxithromycin, doxycycline (e.g., DORYX™, DOXYHEXAL™, DOXYLIN™), minocycline (e.g., MINOCIN™, MINOMYCIN™, AKAMIN™), clarithromycin (e.g., BIAXIN™) and/or nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, ornidazole, megazol, azanidazole) is the at least fourth antibiotic,
and optionally the nitroimidazole is formulated for administration to be cycled 2 weeks on and 2 weeks off.
[00015] In alternative embodiments, the at least three different antibiotics comprise
clarithromycin, rifabutin and furazolidone. Alternatively, the at least three antibiotics comprise rifabutin, azithromycin and doxycycline. The rifabutin, azithromycin and doxycycline may be combined with vitamin D.
[00016] In alternative embodiments, the pharmaceutical compositions, formulations, or products of manufacture further comprises: (a) a vitamin E, a tocotrienol, a natural tocopherol or a tocochromanol, a vitamin D, or any combination thereof, wherein optionally the vitamin D is formulated for use in doses of up to about 5000 to 20,000 units per day, optionally to achieve blood levels of about 150 to 375 nmol/l; (b) a penicillamine, or DEPEN™ or CUPRIMINE™; (c) an acetylcysteine or N-acetylcysteine (NAC), or ACETADOTE™, FLUIMUCIL™, MUCOMYST™; or (d) any combination of (a) to (c). In alternative embodiments, Vitamin D needs to be used in higher than expected doses, as we have shown in patients, for example, at about 5000 to 20,000 units per day to achieve blood levels near the top of normal range of around 200 to 375 nmol/l. These levels are non-toxic, for toxicity to occur much higher levels need to be reached.
[00017] In alternative embodiments, the pharmaceutical compositions, formulations, or products of manufacture further comprises: an agent selected from other medications used in the management of coronary and other vascular disease, other medications that enhance host defence mechanisms important in the eradication of intracellular pathogens, selective and non- selective cyclooxygenase inhibitors; other antiplatelet drugs; betablockers; antiarrhythmics; calcium channel blockers; other anticoagulant drugs; nitrate medicines and HMG-Coareductase inhibitors; immune response modifiers selected from cytokines; colony stimulating factors; tumour necrosis factors alpha and beta; interferon alpha, beta and gamma; peptides which bind to macrophage and lymphocyte surface receptors: glycoproteins which mimic cytokines; and other mediator molecules; prednisone and related steroids, azathioprine, mofetil mycofenolate and related purine antagonists, cyclophosphamide and related alkylating agents, methotrexate and related folate antagonists, thalidomide, chloroquine and related antimalarial compounds, levamisole, cyclosporin A, rapamycin and/or FK506.
[00018] In alternative embodiments, the pharmaceutical compositions, formulations, or products of manufacture are formulated for parenteral or enteral delivery, or for oral delivery, optionally in a capsule, a tablet, a geltab or a solution or a liquid, or as an aerosol, wherein optionally the at least three different antibiotics, or at least two antibiotic, or all active agents are in one formulation, optionally a capsule, a tablet, a geltab or a solution or liquid.
[00019] In alternative embodiments, the product of manufacture is an implant.
[00020] In alternative embodiments, provided are methods for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non- vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including
pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease, the method comprising administration to an individual in need thereof a pharmaceutical composition, a formulation, or a product of manufacture as provided herein.
[00021] In alternative embodiments, the methods further comprise administration of:
(a) vitamin E or tocotrienol or equivalents (optionally comprising vitamin E or tocochromanol either as a natural Tocopherol or Tocotrienol), optionally added in a cyclic fashion, optionally from between daily to weekly administrations; and/or
(b) vitamin D, optionally administered to upper limit of normal levels, optionally administered in dosages of at least about 5,000 to about 20,000 units per day, optionally until levels are reached which are also capable of killing an intracellular infectious agent and reducing intracellular persistence of the intracellular infectious agent, optionally Chlamydophila pneumonia within macrophages.
[00022] In alternative embodiments, of the methods the pharmaceutical composition or formulation is administered parenterally or enterally, or orally, optionally in a capsule, a tablet, a geltab or a solution or a liquid, or as an aerosol, wherein optionally the at least three different antibiotics, or at least two antibiotic, or all active agents are in one formulation, optionally a capsule, a tablet, a geltab or a solution or liquid, and optionally each active agent is formulated in a separate product of manufacture, optionally each active agent in a separate capsule, tablet, geltab, solution or liquid.
[00023] In alternative embodiments, provided are uses of a pharmaceutical composition, formulation, or a product of manufacture as provided herein for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non-vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including
pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease, - arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
[00024] In alternative embodiments, provided are pharmaceutical compositions, formulations, products of manufacture as provided herein for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for use in the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non-vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including
pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
[00025] The details of one or more exemplary embodiments of the invention are set forth in this description. Other features, objects, and advantages of the invention will be apparent from the description and from the claims.
[00026] All publications, patents, patent applications cited herein are hereby expressly incorporated by reference for all purposes. [00027] In alternative embodiments, provided is the use of the pharmaceutical composition, formulation, or product of manufacture of any one of claims 1 to 5 for the manufacture of a medicament for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for use in the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non- vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
Detailed Description
[00028] In alternative embodiments, provided are pharmaceutical compositions and methods for treatment, amelioration and prevention of infection-associated blood vessel diseases, and also for the treatment, amelioration and prevention of non-vessel diseases affected by infective agents which can be treated by these compositions. In alternative embodiments, one common pathogen targeted by compositions and methods as provided herein is Chlamydia and
Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae which also infects humans. In alternative embodiments, pathogens targeted and infections (diseases) treated, ameliorated, or prevented by compositions and methods as provided herein include Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellae eae, including cat scratch disease.
[00029] In alternative embodiments, provided herein are methods and pharmaceutical compositions for the treatment, amelioration and prevention of vascular complications of Chlamydia infections but also disorders resulting from or aggravated by such infections. Such disorders include asthma, chronic obstructive lung disease, dementia, urinary and gynaecologic mucosal Chlamydial infections.
[00030] In alternative embodiments, provided are methods for the treatment, amelioration or prevention of a condition or disease associated with infection by Chlamydial infections, including Chlamydophila pneumoniae (Cpn), or other infections as listed above, in a patient in need of such treatment or prevention.
[00031] In alternative embodiments, compositions and methods as provided herein comprise or comprise administration to an individual (e.g., a patient or an animal) of an affective amount of at least three different antibiotics selected from the group consisting of: macrolides, quinolones, chloramphenicol, cephalosporins, nitazoxanide, furazolidones, lincomycins, aminoglycosides, carbapenems, glycopeptides, glycocyclines, isoniazid, streptogramins, rifamycins/ansamycins, sulphonamides, oxazolidinones, nitrofurans and nitroimidazoles.
[00032] alternative embodiments, compositions and methods as provided herein comprise or comprise administration to an individual (e.g., a patient or an animal) of an affective amount of at least three different antibiotics selected from the group consisting of: clarithromycin, rifabutin and furazolidone. Alternatively, the at least three antibiotics comprise rifabutin, azithromycin and doxycycline. The rifabutin, azithromycin and doxycycline may be combined with vitamin D.
[00033] In alternative embodiments, compositions and methods as provided herein comprise or comprise administration to an individual (e.g., a patient or an animal) of an affective amount of at least three different antibiotics selected from the group consisting of: rifalazil, rifabutin, omiganan, radezolid (RX-1741), torezolid, RWJ-416457, ceftobiprole, ceftaroline, iclaprim, garenoxacin, cethromycin and/or telithromycin (part of the macrolide group), tigecycline, minocycline and tetracycline. [00034] Tigecycline is a novel glycylcycline, but it remains a tetracycline derivative which has good activity against Chlamydophila pneumoniae (Cpn). A new class of macrolide derivatives called ketolides, which includes telithromycin tend to have similar high activity as
clarithromycin possesses, but some isolates are more sensitive than others. The most active of the macrolides used in compositions and methods as provided herein is cethromycin. In alternative embodiments, other anti-Cpn and other infective agent medications used in compositions and methods as provided herein include vancomycin, gentamicin, rifaximin, ampicillin, streptomycin, trimethoprim/sulfamethoxazole. In alternative embodiments, novel inhibitors of peptide deformylase that can be used include NVP-PDF386/ABT/773 and
Des/Quinolone/BMS/284756. These are highly powerful new antimicrobial agents emerging in the treatment of Cpn.
[00035] In alternative embodiments, a three-drug regimen as provided herein comprises rifampicin, azithromycin and moxifloxacin, optionally in a ramping-up dose, a feature observed by the inventor to permit treatment with the combination without adverse effects. In alternative embodiments, a three-drug regimen as provided herein comprises rifabutin and clarithromycin.
[00036] In alternative embodiments, provided are methods for treating, ameliorating or preventing in individuals, e.g., patients or animals, with a previous or current infection with Cpn, or other infections mentioned above by administering at least three antimicrobial agents listed above.
[00037] In alternative embodiments, to prevent the development of the persistent forms of Cpn a supplemental vitamin E or tocotrienol will be added in a cyclic fashion from between second daily to weekly; and these can comprise vitamin E or tocochromanol either as being a natural tocopherol or tocotrienol. The addition of the vitamin E derivatives can markedly reduce the aberrant body development accelerating the destruction of Chlamydia in human lymphocytes.
[00038] In alternative embodiments, compositions and methods also comprise the addition of vitamin D to upper limit of normal levels by ingesting at least 5,000 - 20,000 units per day, until levels are reached, which are also capable of killing the Cpn and reducing intracellular persistence of the intracellular agent.
[00039] In alternative embodiments, the cycling of nitroimidazoles such as metronidazole, tinidazole, omidazole and secnidazole, also prevents the formation of the resistant intracellular reticulate bodies (RBs) and can be inserted to the cycling protocol of three antibiotics as the fourth antibiotic, or metronidazole, tinidazole, omidazole, secnidazole, roxithromycin, doxycycline, minocycline, clarithromycin or nitroimidazole is the fourth antibiotic can be the fourth antibiotic, in a pharmaceutical composition, formulation, or a product of manufacture as provided herein.
[00040] In alternative embodiments, a three drug regime as provided herein comprises rifampicin, azithromycin and moxifloxacin, optionally avoiding tetracyclines as they can inhibit the production of elementary bodies.
[00041] In alternative embodiments, compositions and methods as provided herein are used for Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease; and the compositions and methods can comprise use of: nitroimidazole, roxithromycin, doxycycline, minocycline, clarithromycin, or minocycline and clarithromycin, optionally combined with a vitamin E and/or vitamin D, optionally in a cycling fashion, or optionally including a nitroimidazole one out of two weeks, or two weeks on and two weeks off, to permit the formation of the susceptible Chlamydophila pneumoniae (Cpn) bodies.
[00042] A number of embodiments of the invention have been described. Nevertheless, it can be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
Examples
Example 1:
[00043] A 50-year-old male patient presenting with 70% left anterior descending (LAD) artery obstruction with positive stress test and reduced blood flow on sestamibi scan
had failed standard cardiac treatment. He commenced treatment with three antibiotics
(clarithromycin, rifabutin and furazolidone). After three months of therapy, the patient reported a complete resolution of angina pain and showed marked improvement of blood
flow on sestamibi test at 6 months. Example 2:
[00044] A 63-year-old female with a positive sestamibi test and decreased blood flow to distal epicardial arteries commenced treatment with three different antibiotics and the addition of 10,000 units vitamin D. The patient reported marked clinical improvement and
the sestamibi scan was also improved at 3 months of combination rifabutin, azithromycin and doxycycline plus vitamin D.

Claims

1. A pharmaceutical composition, formulation, or a product of manufacture, comprising:
(a) at least three different antibiotics selected from the group consisting of:
(i) a macrolide (e.g., azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin), a quinolone (e.g., fluoroquinolone), chloramphenicol (e.g., PENTAMYCETIN™, CHLOROMYCETIN™), a cephalosporin, a nitazoxanide (e.g., ALINIA™, NIZONIDE™), a furazolidone (e.g., FUROXONE™, DEPEND AL-M™), a lincomycin or clindamycin (e.g., CLEOCIN™, CLINACIN™), an aminoglycoside (e.g., streptomycin), a carbapenem (e.g., imipenem, meropenem, ertapenem, doripenem, panipenem or betamipron, biapenem,
tebipenem), a glycopeptide (e.g., vancomycin, teicoplanin, telavancin, ramoplanin, decaplanin), a glycocycline (e.g., tigecycline), a streptogramin (e.g., quinupristin/dalfopristin, pristinamycin, virginiamycin), a rifamycin (e.g., rifampicin (or rifampin), rifabutin, rifapentine, rifalazil, rifaximin, rifamycin SV (or AEMCOLO™)) an ansamycin (e.g., streptovaricin, geldanamycin, rifamycin), a sulphonamide (e.g., sulfadimethoxine, sulfamethoxypyridazine,
sulfametoxydiazine, sulfadoxine, sulfametopyrazine, terephtyl), an oxazolidinone (e..g., 2- oxazolidone, linezolid, posizolid, tedizolid, radezolid, cycloserine) and/or a nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, omidazole, megazol, azanidazole); or
(ii) rifalazil, rifabutin (e.g., MYCOBUTIN™), omiganan (or omiganan
pentahydrochloride), radezolid (RX-1741), torezolid, RWJ-416457, ceftobiprole (or
ZEVTERA™, MABELIO™), a nitrofuran (e.g., difurazone, furazolidone, nifurfoline, nifuroxazide, nifurquinazol), isoniazid (e.g., HYDRA™, HYZYD™, ISOVIT™), ceftaroline (e.g., ceftaroline fosamil, or TEFLARO™, ZINFORO™), iclaprim, garenoxacin, cethromycin (e.g., RESTANZA™) and/or telithromycin (e.g., KETEK™) (part of the macrolide group), doxycycline, tigecycline (e.g., TYGACIL™), minocycline (e.g., MINOCIN™, AKAMIN™) and / or a tetracycline (e.g., SUMYCIN™); or,
(iii) a combination of (i) and (ii); or
(b) the pharmaceutical composition, formulation, or a product of manufacture of (a), further comprising at least a fourth antibiotic, and optionally a metronidazole (e.g., FLAGYL™, METRO™), tinidazole (e.g., FASIGYN™, SIMPLOTAN™, TINDAMAX™), ornidazole (e.g., XYNOR™), secnidazole (e.g., FLAGENTYL, SINDOSE™, SECNI™L, SOLOSEC™), roxithromycin, doxycycline (e.g., DORYX™, DOXYHEXAL™, DOXYLIN™), minocycline (e.g., MINOCIN™, MINOMYCIN™, AKAMIN™), clarithromycin (e.g., BIAXIN™) and/or nitroimidazole (e.g., metronidazole, tinidazole, nimorazole, dimetridazole, pretomanid, ornidazole, megazol, azanidazole) is the at least fourth antibiotic,
and optionally the nitroimidazole is formulated for administration to be cycled 2 weeks on and 2 weeks off.
2. The pharmaceutical composition, formulation, or a product of manufacture of claim 1, wherein the at least three different antibiotics comprise:
(a) rifampicin, azithromycin and moxifloxacin, optionally in a ramping-up dose (or formulated for a ramping up dosage regimen);
(b) at least comprises rifabutin, and clarithromycin or azithromycin;
(c) at least comprises rifabutin and minocycline;
(d) at least comprises rifabutin and azithromycin;
(e) at least comprises rifabutin and clarithromycin; or
(f) comprises rifabutin, azithromycin and minocycline.
3. The pharmaceutical composition, formulation, or a product of manufacture of claim 1, wherein the at least three different antibiotics comprise clarithromycin, rifabutin and furazolidone.
4. The pharmaceutical composition, formulation, or a product of manufacture of claim 1, wherein the at least three different antibiotics comprise rifabutin, azithromycin and doxycycline.
5. The pharmaceutical composition, formulation, or a product of manufacture of any one of the preceding claims, further comprising:
(a) a vitamin E, a tocotrienol, a natural tocopherol or a tocochromanol, a vitamin D, or any combination thereof,
wherein optionally the vitamin D is formulated for use in doses of up to about 5000 to 20,000 units per day, optionally to achieve (reach) blood levels of about 150 to 375 nmol/l;
(b) a penicillamine, or DEPEN™ or CETPRIMINE™; (c) an acetylcysteine or N-acetylcysteine (NAC), or ACETADOTE™, FLUIMUCIL™, MUCOMYST™; or
(d) any combination of (a) to (c).
6. The pharmaceutical composition, formulation, or a product of manufacture of any one of the preceding claims, further comprising: an agent selected from other medications used in the management of coronary and other vascular disease, other medications that enhance host defence mechanisms important in the eradication of intracellular pathogens, selective and non- selective cyclooxygenase inhibitors; other antiplatelet drugs; betablockers; antiarrhythmics; calcium channel blockers; other anticoagulant drugs; nitrate medicines and HMG-Coareductase inhibitors; immune response modifiers selected from cytokines; colony stimulating factors; tumour necrosis factors alpha and beta; interferon alpha, beta and gamma; peptides which bind to macrophage and lymphocyte surface receptors: glycoproteins which mimic cytokines; and other mediator molecules; prednisone and related steroids, azathioprine, mofetil mycofenolate and related purine antagonists, cyclophosphamide and related alkylating agents, methotrexate and related folate antagonists, thalidomide, chloroquine and related antimalarial compounds, levamisole, cyclosporin A, rapamycin and/or FK506.
7. The pharmaceutical composition, formulation, or a product of manufacture of any one of the preceding claims, formulated for parenteral or enteral delivery, or for oral delivery, optionally in a capsule, a tablet, a geltab or a solution or a liquid, or as an aerosol,
wherein optionally the at least three different antibiotics, or at least two antibiotic, or all active agents are in one formulation, optionally a capsule, a tablet, a geltab or a solution or liquid.
8. A method for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non- vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae, - a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease,
the method comprising administration to an individual in need thereof a pharmaceutical composition, a formulation, or a product of manufacture of any one of the preceding claims.
9. The method of claim 8, further comprising administration of:
(a) vitamin E or tocotrienol or equivalents (optionally comprising vitamin E or tocochromanol either as a natural Tocopherol or Tocotrienol), optionally added in a cyclic fashion, optionally from between daily to weekly administrations; and/or
(b) vitamin D, optionally administered to upper limit of normal levels, optionally administered in dosages of at least about 5,000 to about 20,000 units per day, optionally until levels are reached which are also capable of killing an intracellular infectious agent and reducing intracellular persistence of the intracellular infectious agent, optionally Chlamydophila pneumoniae.
10. The method of claim 8 or claim 9, wherein the pharmaceutical composition or formulation is administered parenterally or enterally, or orally, optionally in a capsule, a tablet, a geltab or a solution or a liquid, or as an aerosol,
wherein optionally the at least three different antibiotics, or at least two antibiotic, or all active agents are in one formulation, optionally a capsule, a tablet, a geltab or a solution or liquid,
and optionally each active agent is formulated in a separate product of manufacture, optionally each active agent in a separate capsule, tablet, geltab, solution or liquid.
11. Use of a pharmaceutical composition, formulation, or a product of manufacture of any one of claims 1 to 7, for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non- vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
12. A pharmaceutical composition, formulation, or a product of manufacture of any one of claims 1 to 7 for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for use in the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non- vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
13. Use of the pharmaceutical composition, formulation, or product of manufacture of any one of claims 1 to 7 for the manufacture of a medicament for inhibiting development of atheroma in arterial vessel walls after invasion by macrophages carrying Chlamydophila pneumoniae (Cpn) to arterial intima, or for use in the treatment, amelioration and prevention of:
- an infection-associated blood vessel disease,
- a non- vessel disease affected by an infective agent,
- a disease or condition caused by Chlamydia or a Chlamydophila species, including pneumoniae, trachomatis and psittaci species which infect humans, including Chlamydophila pneumoniae,
- a disease or condition caused by Mycoplasma, Listeria, Leptospirosis, Q fever or Coxiella burnetii infection, Lyme disease or Lyme borreliosis or any Borrelia infection, and Bartonella or of the family Bartonellaceae, including cat scratch disease,
- arterial inflammation, atheroma or arterial foam cells,
- chronic arthritis, or
- Alzheimer’s disease or a dementia, wherein optionally the dementia is vascular dementia, Lewy body dementia or frontotemporal dementia, or a dementia caused or a result of normal pressure hydrocephalus, Parkinson's disease dementia, syphilis or Creutzfeldt-Jakob disease.
PCT/AU2019/050078 2018-02-01 2019-02-01 Compositions for treating infective arterial diseases and related conditions Ceased WO2019148249A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201980006904.6A CN111757732A (en) 2018-02-01 2019-02-01 Compositions for the treatment of infectious arterial disease and related conditions
EP19747153.5A EP3746073A4 (en) 2018-02-01 2019-02-01 COMPOSITIONS FOR TREATMENT OF INFECTIOUS ARTERIAL DISEASES AND RELATED CONDITIONS
AU2019214017A AU2019214017A1 (en) 2018-02-01 2019-02-01 Compositions for treating infective arterial diseases and related conditions
CA3086850A CA3086850A1 (en) 2018-02-01 2019-02-01 Compositions for treating infective arterial diseases and related conditions
US16/958,299 US20210052557A1 (en) 2018-02-01 2019-02-01 Compositions for treating infective arterial diseases and related conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625259P 2018-02-01 2018-02-01
US62/625,259 2018-02-01

Publications (1)

Publication Number Publication Date
WO2019148249A1 true WO2019148249A1 (en) 2019-08-08

Family

ID=67479096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2019/050078 Ceased WO2019148249A1 (en) 2018-02-01 2019-02-01 Compositions for treating infective arterial diseases and related conditions

Country Status (6)

Country Link
US (1) US20210052557A1 (en)
EP (1) EP3746073A4 (en)
CN (1) CN111757732A (en)
AU (1) AU2019214017A1 (en)
CA (1) CA3086850A1 (en)
WO (1) WO2019148249A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11473917B2 (en) 2020-07-14 2022-10-18 Argo AI, LLC System for augmenting autonomous vehicle perception using smart nodes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001378A1 (en) * 1998-06-30 2000-01-13 Karl William Baumgart Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
WO2013181694A1 (en) * 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
US20150190415A1 (en) * 2011-09-14 2015-07-09 Thomas J. Lewis Novel compositions comprising macrolide and tetracycline and their uses
WO2019033142A1 (en) * 2017-08-15 2019-02-21 Borody Thomas J Compositions, devices and methods for treating autism
WO2019040969A1 (en) * 2017-08-31 2019-03-07 Centre For Digestive Diseases Compositions, devices and methods for treating obsessive-compulsive disorder
WO2019060553A1 (en) * 2017-09-20 2019-03-28 Atopic Medical, LLC Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884784B1 (en) * 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US20040176404A1 (en) * 2002-12-12 2004-09-09 Sayada Chalom B. Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
WO2007103149A2 (en) * 2006-03-03 2007-09-13 Activbiotics, Inc. Treatment of atherosclerotic disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001378A1 (en) * 1998-06-30 2000-01-13 Karl William Baumgart Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
US20150190415A1 (en) * 2011-09-14 2015-07-09 Thomas J. Lewis Novel compositions comprising macrolide and tetracycline and their uses
WO2013181694A1 (en) * 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
WO2019033142A1 (en) * 2017-08-15 2019-02-21 Borody Thomas J Compositions, devices and methods for treating autism
WO2019040969A1 (en) * 2017-08-31 2019-03-07 Centre For Digestive Diseases Compositions, devices and methods for treating obsessive-compulsive disorder
WO2019060553A1 (en) * 2017-09-20 2019-03-28 Atopic Medical, LLC Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FREIDANK ET AL.: "In Vitro Susceptibilities of Chlamydia pneumoniae Isolates from German Patients and Synergistic Activity of Antibiotic Combinations", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 43, no. 7, 1999, pages 1808 - 1810, XP000949492 *
OVERTON ET AL.: "Cluster of invasive Mycobacteria chimaera infections following cardiac surgery demonstrating novel clinical features and risks of aortic valve replacement", INTERNAL MEDICINE JOURNAL, vol. 48, no. 12, 5 December 2018 (2018-12-05), pages 1514 - 1520, XP055627697, ISSN: 1444-0903, DOI: 10.1111/imj.14093 *
PATRICK BASU . NIRAJ J.SHAH ,KAVYA MITTIMANI ,RAVI SIRIKI ,SRILAKSHMI ATLURI ,SAKINA FARHAT ,A.RAHAMAN: "Rifabutin, Omeprazole, Alinia and Doxycycline Therapy for Prior Treatment Failure Helicobacter pylori (HP) Population - A Randomized Open Label Clinical Pilot Study -Road Trial", GASTROENTEROLOGY, vol. 144, no. 5, 31 May 2013 (2013-05-31), pages S-336, XP055718060, DOI: 10.1016/S0016-5085(13)61237-8 *
PRYJMA ET AL.: "Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018, vol. 62, no. 8, 14 May 2018 (2018-05-14), pages 10, XP055627689 *
ROTHSTEIN ET AL.: "Development potential of rifalazil and other benzoxazinorifamycins", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 15, no. 6, 2006, pages 603 - 623, XP002644790, DOI: 10.1517/13543784.15.6.603 *
See also references of EP3746073A4 *

Also Published As

Publication number Publication date
CA3086850A1 (en) 2019-08-08
EP3746073A4 (en) 2021-11-17
CN111757732A (en) 2020-10-09
AU2019214017A1 (en) 2020-07-16
EP3746073A1 (en) 2020-12-09
US20210052557A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP5782615B2 (en) Methods of treatment using a single dose of oritavancin
TWI690317B (en) Combination therapy for the treatment of drug-resistant bacterial infections
Kowalski et al. Intracameral Vigamox®(moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model
JP2004339238A5 (en)
JP2006335773A (en) Antibiotic administration method
JP2006501310A (en) Methods and reagents for treating Clostridium difficile infection and related diseases
Dunne et al. A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270)
Junita et al. The effect of glutathione as adjuvant therapy on levels of TNF-α and IL-10 in wistar rat peritonitis model
WO2019148249A1 (en) Compositions for treating infective arterial diseases and related conditions
EA016803B1 (en) TREATMENT OF INFECTIOUS DISEASES
KR102893477B1 (en) Treatment of diabetic foot infections
US20230364065A1 (en) Antibiotic combination therapies
RS59551B1 (en) Compositions and methods for using lamellar bodies for therapeutic purposes
Kobayashi et al. Safety of linezolid, rifampicin, and clindamycin combination therapy in patients with prosthetic joint infection
US20200399308A1 (en) Compounds and methods for eliciting antimicrobial activity
RU2232592C2 (en) Method for treatment of bacterial infection
WO2025030169A2 (en) Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
WO2020112605A1 (en) Compounds and methods for treating chronic microbial infections
EA007713B1 (en) Combinations of dalfopristine/quinupristine with cefpirome
GB2403653A (en) Use of fluoroquinone antibiotics for the treatment of plague

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19747153

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 3086850

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019214017

Country of ref document: AU

Date of ref document: 20190201

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019747153

Country of ref document: EP

Effective date: 20200901